A murine CD8+ T cell epitope identified in the receptor-binding domain of the SARS-CoV-2 spike protein

Cited 5 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorJihyun Yang-
dc.contributor.authorEunjin Kim-
dc.contributor.authorJ S Lee-
dc.contributor.authorHaryoung Poo-
dc.date.accessioned2021-07-06T03:31:53Z-
dc.date.available2021-07-06T03:31:53Z-
dc.date.issued2021-
dc.identifier.issn2076-393X-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/24456-
dc.description.abstractThe ongoing COVID-19 pandemic caused by SARS-CoV-2 has posed a devastating threat worldwide. The receptor-binding domain (RBD) of the spike protein is one of the most important antigens for SARS-CoV-2 vaccines, while the analysis of CD8 cytotoxic T lymphocyte activity in preclinical studies using mouse models is critical for evaluating vaccine efficacy. Here, we immunized C57BL/6 wild-type mice and transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with the SARS-CoV-2 RBD protein to evaluate the IFN-γ-producing T cells in the splenocytes of the immunized mice using an overlapping peptide pool by an enzyme-linked immunospot assay and flow cytometry. We identified SARS-CoV-2 S395-404 as a major histocompatibility complex (MHC) class I-restricted epitope for the RBD-specific CD8 T cell responses in C57BL/6 mice.-
dc.publisherMDPI-
dc.titleA murine CD8+ T cell epitope identified in the receptor-binding domain of the SARS-CoV-2 spike protein-
dc.title.alternativeA murine CD8+ T cell epitope identified in the receptor-binding domain of the SARS-CoV-2 spike protein-
dc.typeArticle-
dc.citation.titleVaccines-
dc.citation.number6-
dc.citation.endPage641-
dc.citation.startPage641-
dc.citation.volume9-
dc.contributor.affiliatedAuthorJihyun Yang-
dc.contributor.affiliatedAuthorEunjin Kim-
dc.contributor.affiliatedAuthorHaryoung Poo-
dc.contributor.alternativeName양지현-
dc.contributor.alternativeName김은진-
dc.contributor.alternativeName이종수-
dc.contributor.alternativeName부하령-
dc.identifier.bibliographicCitationVaccines, vol. 9, no. 6, pp. 641-641-
dc.identifier.doi10.3390/vaccines9060641-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordCell-mediated immunity-
dc.subject.keywordCD8 cytotoxic T lymphocyte-
dc.subject.keywordEpitope-
dc.subject.keywordVaccine-
dc.subject.localSARS-CoV-2-
dc.subject.localSARS-Cov-2-
dc.subject.localCell-mediated immunity-
dc.subject.localcell-mediated immunity-
dc.subject.localCD8 cytotoxic T lymphocyte-
dc.subject.localEpitope-
dc.subject.localepitope-
dc.subject.localvaccine-
dc.subject.localvaccines-
dc.subject.localVaccine-
dc.description.journalClassY-
Appears in Collections:
Division of Research on National Challenges > Infectious Disease Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.